Chronic Leukemias

Chronic Leukemias

A collection of features and news articles published in ASH Clinical News related to chronic leukemias.

Higher Childhood Leukemia Risk in Offspring Raises Questions About Hormonal Contraceptive Safety

Children born to women who were using hormonal contraception within three months of pregnancy and during pregnancy have a higher risk of developing myeloid...

How I Treat In Brief: Managing Ibrutinib-Refractory Chronic Lymphocytic Leukemia

Jennifer A. Woyach, MD, associate professor at the Ohio State University Comprehensive Cancer Center, wrote about her strategy for the management of patients with...

Demystifying Epigenetics in Hematology

In the early 20th century, German researcher Theodor Boveri described the basic tenets of tumor biology: Cells can turn cancerous when they lose the...

Next Steps After TKIs for Patient With Chronic-Phase CML?

Here’s how readers responded to a You Make the Call question about the next steps after TKIs for patient with chronic-phase chronic myeloid leukemia. Disclaimer:...

Next Steps After TKIs for Patient With Chronic-Phase CML?

This month, Michael Deininger, MD, PhD, discusses treatment for a patient with chronic-phase chronic myeloid leukemia (CML) whose BCR/ABL transcript levels are rising. And don't...
WIB_icon

Researchers Identify Cancer Gene Mutations Associated with Poor Outcomes in CML

Despite the good outcomes experienced by most patients with chronic-phase chronic myeloid leukemia (CP-CML) treated with tyrosine kinase inhibitors (TKIs), a subset do not...

Is Chronic Lymphocytic Leukemia Curable With Newer Agents?

Chronic lymphocytic leukemia (CLL) has long been considered an incurable disease. The goal of traditional frontline treatments is to minimize disease burden and allow...

EURO-SKI: Can Patients With CML Stop Tyrosine Kinase Inhibitors?

Treatment with tyrosine kinase inhibitors (TKIs) like imatinib, nilotinib, and dasatinib, has increased the rates of survival and response over previously available therapies for...

Phase III BFORE Trial: Bosutinib Beats Imatinib for Frontline CML Treatment

Patients with previously untreated chronic myeloid leukemia (CML) who received bosutinib were more likely than those who received imatinib to respond to treatment and...
WIB_icon

Long-Term PACE Follow-Up Confirms Ponatinib’s Benefit in CP-CML

At five-year follow-up, treatment with the third-generation tyrosine kinase inhibitor (TKI) ponatinib led to deep and durable responses in patients with heavily pretreated chronic-phase...
Advertisement

Current Issue

December 2018, Volume 4, Issue 14

This issue features a look at the consequences of medical errors, an update on the Cancer Moonshot Initiative, a preview of 2018 ASH Annual Meeting, and more.